Nothing Special   »   [go: up one dir, main page]

UY34154A - Dosificación y administración de anticuerpos anti-erbb3 en combinación con paclitaxel. - Google Patents

Dosificación y administración de anticuerpos anti-erbb3 en combinación con paclitaxel.

Info

Publication number
UY34154A
UY34154A UY0001034154A UY34154A UY34154A UY 34154 A UY34154 A UY 34154A UY 0001034154 A UY0001034154 A UY 0001034154A UY 34154 A UY34154 A UY 34154A UY 34154 A UY34154 A UY 34154A
Authority
UY
Uruguay
Prior art keywords
paclitaxel
dosage
administration
combination
erbb3 antibodies
Prior art date
Application number
UY0001034154A
Other languages
English (en)
Inventor
Kubasek William
Moyo Victor
Nering Rachel
Dhindsa Navreet
Macbeath Gavin
Pearlberg Joseph
Tabah-Fisch Isabelle
Kalra Ashish
Original Assignee
Merrimack Pharmaceuticals Inc
Sanofi Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merrimack Pharmaceuticals Inc, Sanofi Sa filed Critical Merrimack Pharmaceuticals Inc
Publication of UY34154A publication Critical patent/UY34154A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/702—Oligosaccharides, i.e. having three to five saccharide radicals attached to each other by glycosidic linkages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

Se proporcionan métodos y composiciones para tratamiento clínico del cáncer de mama utilizando anticuerpos anti-ErbB3 combinados con paclitaxel.
UY0001034154A 2011-06-24 2012-06-22 Dosificación y administración de anticuerpos anti-erbb3 en combinación con paclitaxel. UY34154A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161500752P 2011-06-24 2011-06-24
US201261596102P 2012-02-07 2012-02-07
FR1252652 2012-03-23

Publications (1)

Publication Number Publication Date
UY34154A true UY34154A (es) 2013-01-31

Family

ID=47422882

Family Applications (1)

Application Number Title Priority Date Filing Date
UY0001034154A UY34154A (es) 2011-06-24 2012-06-22 Dosificación y administración de anticuerpos anti-erbb3 en combinación con paclitaxel.

Country Status (4)

Country Link
AU (1) AU2012273361A1 (es)
TW (1) TW201315481A (es)
UY (1) UY34154A (es)
WO (1) WO2012177440A1 (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RS53042B (en) 2007-02-16 2014-04-30 Merrimack Pharmaceuticals Inc. ANTIBODIES AGAINST ERBB3 AND THEIR USES
EA201201186A1 (ru) 2010-03-11 2013-11-29 Мерримак Фармасьютикалс, Инк. ИСПОЛЬЗОВАНИЕ ErbB3 ИНГИБИТОРОВ В ЛЕЧЕНИИ ТРИЖДЫ НЕГАТИВНОГО И БАЗАЛЬНО-ПОДОБНОГО ВИДОВ РАКА МОЛОЧНОЙ ЖЕЛЕЗЫ
WO2015100459A2 (en) * 2013-12-27 2015-07-02 Merrimack Pharmaceuticals, Inc. Biomarker profiles for predicting outcomes of cancer therapy with erbb3 inhibitors and/or chemotherapies
US10184006B2 (en) 2015-06-04 2019-01-22 Merrimack Pharmaceuticals, Inc. Biomarkers for predicting outcomes of cancer therapy with ErbB3 inhibitors
WO2021043673A1 (en) * 2019-09-02 2021-03-11 Syddansk Universitet P-gp inducers as protectors against chemotherapy-induced side effects, such as peripheral neuropathy (cipn) and hair loss

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2094870A4 (en) * 2006-11-03 2010-05-05 Univ Texas BIFUNCTIONAL PREDICTORS FOR SENSITIVITY AND RESISTANCE TO ANTI-CANCER TREATMENT
RS53042B (en) * 2007-02-16 2014-04-30 Merrimack Pharmaceuticals Inc. ANTIBODIES AGAINST ERBB3 AND THEIR USES

Also Published As

Publication number Publication date
AU2012273361A1 (en) 2013-03-21
TW201315481A (zh) 2013-04-16
WO2012177440A1 (en) 2012-12-27

Similar Documents

Publication Publication Date Title
UY34721A (es) Anticuerpos anti-hla-b*27 y usos de éstos.
EA201500314A1 (ru) Лекарственные формы энзалутамида
EA201491447A1 (ru) Ендиины, их конъюгаты и способы их получения и применения
EA201590993A1 (ru) Гетеродимерные иммуноглобулины
UY34782A (es) Anticuerpos humanos para fel d1 y métodos para usarlos.
EA201400178A1 (ru) Лечение рака молочной железы
UY34456A (es) Anticuerpos anti-il-36r
EA201992133A1 (ru) Производные пиперидино-пиримидина для лечения вирусных инфекций
EA201491224A1 (ru) Анти-псф-тау-антитела и их применение
EA201390804A1 (ru) Лекарственная форма лакозамида для приема один раз в сутки
UY34876A (es) Anticuerpos anti-egfr y usos de los mismos
EA201391719A1 (ru) Хиназолиновые производные для лечения вирусных инфекций и дальнейших заболеваний
EA201491947A1 (ru) Антитела и иммуноконъюгаты к ly6e и способы применения
EA201591887A1 (ru) Макроциклические деазаоксипурины для лечения вирусных инфекций
UY34206A (es) Anticuerpo monoclonal de interleucina-31
UY34582A (es) Anticuerpos anti-cxcr3
EA201491357A1 (ru) Анти-lrp5 антитела и способы их применения
EA201490778A1 (ru) АНТИТЕЛА ПРОТИВ HtrA1 И СПОСОБЫ ПРИМЕНЕНИЯ
EA201590731A1 (ru) Антитела к гемагглютинину и способы применения
UA111098C2 (uk) Проліки адреномедуліну на основі поліетиленгліколю і їх застосування
UY34178A (es) Dosificación y administración de anticuerpos anti-erbb3 en combinación con paclitaxel para el tratamiento de cánceres ginecológicos.
MX2014001368A (es) Soluciones anti-inflamatorias estables para inyección.
CO7151478A2 (es) Formulaciones estabilizadas que contienen anticuerpos anti-dll4
EA201590503A1 (ru) Альфа-1-микроглобулин для применения в лечении заболеваний, связанных с митохондриями
UY34154A (es) Dosificación y administración de anticuerpos anti-erbb3 en combinación con paclitaxel.